3C GROUPS Acquires 100% of Blue Ocean Robotics

Blue Ocean Robotics has achieved a commercial breakthrough in the pharmaceutical sector, delivering revenue growth and moving steadily towards profitability. As part of this positive development, 3C GROUPS is in the process of acquiring the remaining shares in the company and will become the sole owner of Blue Ocean Robotics. 

With a renewed commercial focus, strengthened leadership, and fresh capital, the future looks brighter than it has in many years for the Odense-based robotics company. 3C GROUPS is currently completing the acquisition of the remaining shares, while Blue Ocean Robotics has successfully restored its equity position.

Although the purchase price of the remaining shares has not been disclosed, investors who reinvested in the company in the first quarter of 2025 - when 3C GROUPS became the majority shareholder - have realized a significant positive return on their investment.

Strategic Focus on the UVD Robot
Blue Ocean Robotics has developed several robotic solutions over the years. In August 2025, however, the company made a strategic decision to concentrate its efforts on its market-leading UVD Robot™, recognizing this as the most mature and commercially attractive market opportunity.

The UVD Robot provides autonomous UV-C disinfection solutions for healthcare, life sciences, and pharmaceutical environments where maintaining sterile conditions is critical.

“I have no hesitation in describing this as a commercial breakthrough for Blue Ocean Robotics, particularly within the pharmaceutical industry, where we now supply robots and cleanroom solutions to some of the world’s largest pharmaceutical companies,” said Søren Vilby, Chairman of Blue Ocean Robotics.

Global pharmaceutical leader AstraZeneca is among a growing number of high-profile customers that have invested in multiple Blue Ocean Robotics solutions.

Strong Progress Towards Profitability
In August 2025, Thomas Knudsen joined Blue Ocean Robotics as CEO. He brings extensive experience in global sales and business development and most recently served as Chief Commercial Officer (CCO) of Mobile Industrial Robots (MiR), part of the Teradyne Group.

The company’s 2025 financial results demonstrate significant progress, with the annual loss reduced by more than 50%, decreasing from DKK 119 million in 2024 to DKK 58 million in 2025.

Following a comprehensive restructuring programme, including the outsourcing of production activities, Blue Ocean Robotics has substantially reduced its cost base, with the full impact now reflected in its financial performance.

For the 2026 financial year, the company expects a result in the range of DKK -15 million to -25 million, representing another significant step forward.

“We are seeing a clear positive impact from our new strategy. We have significantly improved our cost structure while sharpening our go-to-market approach with an increased focus on the pharmaceutical market. The results are evident in stronger sales performance and a rapidly expanding pipeline of opportunities. We are firmly on track towards profitability,” said Thomas Knudsen, CEO of Blue Ocean Robotics.

Blue Ocean Robotics generates revenue from three core business areas: direct sales of robots, robot leasing, and service agreements for installed robots.

 Key figures – Blue Ocean Robotics ApS (DKK million) 

Learn more about the UVD Robot: www.uvd-robots.com

For further information

Thomas Knudsen, CEO
Blue Ocean Robotics
Phone: +45 25 25 68 05

Søren Vilby, Chairman of the Board
Blue Ocean Robotics
Phone: +45 20 80 11 18